Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms
Joseph Tripodi1, Ronald Hoffman1, Vesna Najfeld2, Rona Weinberg31The Myeloproliferative Disorders Program, Tisch Cancer Institute, Department of Medicine and 2Department of Medicine and Pathology, Mount Sinai School of Medicine, 3The Myeloproliferative Disorders Program, Cellular Therapy Laboratory,...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2010-09-01
|
Series: | Cancer Management and Research |
Online Access: | http://www.dovepress.com/frequency-of-heterozygous-tet2-deletions-in-myeloproliferative-neoplas-a5301 |
id |
doaj-9ea16d3c3f8b46e2b717d7aa8bcaef15 |
---|---|
record_format |
Article |
spelling |
doaj-9ea16d3c3f8b46e2b717d7aa8bcaef152020-11-25T00:48:40ZengDove Medical PressCancer Management and Research1179-13222010-09-012010default219223Frequency of heterozygous TET2 deletions in myeloproliferative neoplasmsJoseph TripodiRonald HoffmanVesna Najfeldet alJoseph Tripodi1, Ronald Hoffman1, Vesna Najfeld2, Rona Weinberg31The Myeloproliferative Disorders Program, Tisch Cancer Institute, Department of Medicine and 2Department of Medicine and Pathology, Mount Sinai School of Medicine, 3The Myeloproliferative Disorders Program, Cellular Therapy Laboratory, The New York Blood Center, New York, NY, USAAbstract: The Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are a group of clonal hematopoietic stem cell disorders with overlapping clinical and cytogenetic features and a variable tendency to evolve into acute leukemia. These diseases not only share overlapping chromosomal abnormalities but also a number of acquired somatic mutations. Recently, mutations in a putative tumor suppressor gene, ten-eleven translocation 2 (TET2) on chromosome 4q24 have been identified in 12% of patients with MPN. Additionally 4q24 chromosomal rearrangements in MPN, including TET2 deletions, have also been observed using conventional cytogenetics. The goal of this study was to investigate the frequency of genomic TET2 rearrangements in MPN using fluorescence in situ hybridization as a more sensitive method for screening and identifying genomic deletions. Among 146 MPN patients, we identified two patients (1.4%) who showed a common 4q24 deletion, including TET2. Our observations also indicated that the frequency of TET2 deletion is increased in patients with an abnormal karyotype (5%).Keywords: TET2, myeloproliferative neoplasms, fluorescence in situ hybridization, cytogenetics http://www.dovepress.com/frequency-of-heterozygous-tet2-deletions-in-myeloproliferative-neoplas-a5301 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Joseph Tripodi Ronald Hoffman Vesna Najfeld et al |
spellingShingle |
Joseph Tripodi Ronald Hoffman Vesna Najfeld et al Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms Cancer Management and Research |
author_facet |
Joseph Tripodi Ronald Hoffman Vesna Najfeld et al |
author_sort |
Joseph Tripodi |
title |
Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms |
title_short |
Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms |
title_full |
Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms |
title_fullStr |
Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms |
title_full_unstemmed |
Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms |
title_sort |
frequency of heterozygous tet2 deletions in myeloproliferative neoplasms |
publisher |
Dove Medical Press |
series |
Cancer Management and Research |
issn |
1179-1322 |
publishDate |
2010-09-01 |
description |
Joseph Tripodi1, Ronald Hoffman1, Vesna Najfeld2, Rona Weinberg31The Myeloproliferative Disorders Program, Tisch Cancer Institute, Department of Medicine and 2Department of Medicine and Pathology, Mount Sinai School of Medicine, 3The Myeloproliferative Disorders Program, Cellular Therapy Laboratory, The New York Blood Center, New York, NY, USAAbstract: The Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are a group of clonal hematopoietic stem cell disorders with overlapping clinical and cytogenetic features and a variable tendency to evolve into acute leukemia. These diseases not only share overlapping chromosomal abnormalities but also a number of acquired somatic mutations. Recently, mutations in a putative tumor suppressor gene, ten-eleven translocation 2 (TET2) on chromosome 4q24 have been identified in 12% of patients with MPN. Additionally 4q24 chromosomal rearrangements in MPN, including TET2 deletions, have also been observed using conventional cytogenetics. The goal of this study was to investigate the frequency of genomic TET2 rearrangements in MPN using fluorescence in situ hybridization as a more sensitive method for screening and identifying genomic deletions. Among 146 MPN patients, we identified two patients (1.4%) who showed a common 4q24 deletion, including TET2. Our observations also indicated that the frequency of TET2 deletion is increased in patients with an abnormal karyotype (5%).Keywords: TET2, myeloproliferative neoplasms, fluorescence in situ hybridization, cytogenetics |
url |
http://www.dovepress.com/frequency-of-heterozygous-tet2-deletions-in-myeloproliferative-neoplas-a5301 |
work_keys_str_mv |
AT josephtripodi frequencyofheterozygoustet2deletionsinmyeloproliferativeneoplasms AT ronaldhoffman frequencyofheterozygoustet2deletionsinmyeloproliferativeneoplasms AT vesnanajfeld frequencyofheterozygoustet2deletionsinmyeloproliferativeneoplasms AT etal frequencyofheterozygoustet2deletionsinmyeloproliferativeneoplasms |
_version_ |
1725255132747137024 |